UCB's New Anti-Epileptic Finally Reaches The Finishing Line
This article was originally published in Scrip
Executive Summary
The EU's CHMP has given the go-ahead for approval for UCB's novel anti-epileptic brivaracetam as Briviact after a development process marked by some bumps in the road.